TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Regimen of Patient-controlled Epidural Analgesia in Laboring Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Parturients receiving Combined Spinal epidural analgesia for labor pain relief.~Exclusion Criteria:~Any patient with failed epidural, delivery within 2 hours of epidural insertion, or Cesarean section will be excluded from the study.

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- GROUP A (Type: None): The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
- GROUP B (Type: None): The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
- GROUP C (Type: None): The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
- GROUP D (Type: None): The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
- GROUP E (Type: None): The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Target aneurysm is an unruptured wide-neck, intracranial, saccular anterior circulation aneurysm (≤ 10 mm) arising from a parent vessel with a diameter of ≥ 2.5 mm and ≤ 4 mm~* Subject understands the nature of the procedure and provides voluntary written informed consent prior to the treatment~* Subject is willing to comply with specified follow-up evaluation~Exclusion Criteria:~* Planned staged procedure~* Currently enrolled in another investigational device or drug study~* Target aneurysm that has been previously treated~* Mycotic, fusiform or dissecting aneurysm~* Admission platelet \<50,000 or any known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy with an INR \>3.0~* A serum creatinine level \> 2.5 mg/dL within 7 days prior to index procedure

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Enterprise (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Local Anaesthetic Following Hernia Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Primary unilateral inguinal hernia~* Aged 18 years or more~Exclusion criteria:~* Bilateral inguinal hernia repairs to be performed at the same procedure.~* Recurrent inguinal hernia~* Patient unable to give informed consent~* Contraindication to the use of local anaesthetic~* Operation to be performed under local or spinal anaesthetic.~* Contraindication to use of diclofenac, fentanyl or paracetamol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Normal saline placebo
- Ropivocaine (Type: ACTIVE_COMPARATOR): Ilioinguinal nerve block with ropivocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically or cytologically proven adenocarcinoma of the prostate~* Documented metastatic prostate adenocarcinoma~* Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging~* Age \>= 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status \<= 2~* Adequate hematologic, renal and hepatic function~* Life expectancy \>= 3 months~Exclusion Criteria:~* Prior chemotherapy, except estramustine~* Prior chemotherapy with docetaxel~* Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)~* One or more contraindications to the use of corticosteroids~* History of cancer-related hypercalcemia

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a St Jude Medial device that is compatible with Merlin.net (remote monitoring)~* Patient has history of atrial fibrillation (non-continuous)~* Patient must be taking a a blood thinner medication other than warfarin or aspirin for atrial fibrillation~* Patient is willing to complete a questionnaire~Exclusion Criteria:~* Patient is in atrial fibrillation all of the time~* Patient has a history of stroke or blood clot~* Patient is on warfarin or coumadin~* Patient cannot be taken off of his blood thinner medication due to another medical condition~* Patient is not capable of sending a remote device transmission to doctor once a week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
- Tailored Anticoagulation (TAC) (Type: EXPERIMENTAL): Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status (WHO) 0-2~* Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received~* HER-2 overexpression 2+ or 3+ using IHC or FISH +~* Measurable disease not in a prior irradiation field (no other concurrent chemotherapy agents)~* No more than 25% of myeloproductive bone marrow irradiated (more than 4 weeks since prior radiotherapy and recovered)~* More than 6 months since prior adjuvant or neoadjuvant chemotherapy and recovered~* No prior first line chemotherapy for metastatic disease~* Endocrine therapy is allowed as adjuvant or first line treatment for metastatic disease~* Paraffin block from the primary tumor available in the research lab~* Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl)~* Adequate cardiac function (LVEF \> 50%)~* Informed consent~Exclusion Criteria:~* Pregnant or nursing~* Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce P-450 cytochrome~* Positive pregnancy test~* Motor or sensory neuropathy \> grade 1 according to NCIC Τoxicity Criteria~* Patients with brain metastatic disease who has not been irradiated or uncontrolled brain metastatic disease after irradiation~* History of allergic reaction attributed to docetaxel~* Psychiatric illness or social situation that would preclude study compliance~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except cured basal cell skin carcinoma and cervical carcinoma in situ

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
- 2 (Type: EXPERIMENTAL): Vinorelbine + Herceptin (VHer)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Clinical inclusion criteria:~* Age ≥18 years~* DM type I or II based on the definitions of the American Diabetes Association~* Angiographically proven CAD~* Angina pectoris, equivalent symptoms, and/or positive stress test, and/or instantaneous flow reserve ≤0.86, and/or fractional flow reserve ≤0.80~* Negative pregnancy test in women with childbearing potential~Angiographic inclusion criteria:~* De-novo lesion in at least one native coronary artery~* Luminal diameter reduction 50-99% assessed by visual estimation~* Target reference vessel diameter 2.5 - 4.0 mm~Clinical exclusion criteria:~* Limited long-term prognosis with a life-expectancy \<12 months~* Contraindications to antiplatelet therapy~* Known allergy against cobalt chrome, everolimus, or polylactic acid~Angiographic exclusion criteria:~* Target lesion located in the left main trunk~* Severe calcification of the target lesion as determined by angiography~* In-stent restenosis~* Bifurcation lesion with planned two-stent strategy~* Chronic total occlusion~* Indication for CABG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Absorb GT1 (Type: EXPERIMENTAL): Bioresorbable everolimus-eluting scaffolds
- Promus (Type: ACTIVE_COMPARATOR): Everolimus-eluting stents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Major patient.~* Fibrosing frontal alopecia or lichen planus pilaris~* Presence of pruritus of the scalp : a positive response to the question do you experience itchy scalp?~* The patient received an information note and did not object to the study~Exclusion Criteria:~* Patients under 18 years of age.~* Other pathologies causing scalp pruritus (seborrheic dermatitis, contact dermatitis, lupus, Quinquaud's decalcifying folliculitis, ectoparasitosis, scalp psoriasis, ringworm, red sclap syndrome, dermatomyositis, central centrifugal cicatricial alopecia (CCCA))~* Refusal to participate by the patient.~* Patient under legal protection (curatorship, guardianship, ...)~* Patient not covered by social security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient (Type: None): patients answer the same questionnaire whether they have frontal alopecia or lichen planus pilaris

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male and female candidates (18 years of age and older) undergoing coronary bypass grafting surgery or valve repair or replacement - Aortic or Tricuspid or Pulmonary valves~* Patients who are not previously on Ranolazine~* Do not have a history of arrhythmia and are not on any antiarrhythmic therapy~* Patients with QTc on a 12 lead EKG of less than or equal to 460 ms~* Patients with estimated Glomerular Filtration Rate (GFR) greater than 30 mL/min/1.73 m2 on the initial lab work~* Available at least 48 hours before surgery~Exclusion criteria:~* Patients who are not undergoing above surgeries~* Patients undergoing surgery for mitral valve replacement/repair~* Patient with cirrhosis~* Pregnant patients~* Patients with chronic atrial fibrillation~* Patients who had prior adverse drug reactions or allergies to Ranolazine~* Patients who are already taking Ranolazine prior to the study~* Patient who are reported HIV Positive (as there are antiretroviral drug interactions)~* Patients who are on drugs listed in Appendix A prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranolazine (Type: ACTIVE_COMPARATOR): The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
- Placebo (Type: PLACEBO_COMPARATOR): Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Taping in the Hemiplegic Patient With a Deficit of the Footbrowers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a stroke occurring in a period ranging from 15 days to a month before inclusion and presenting left or right hemiplegia.~* Voluntary motricity of the dorsal flexors of the foot greater than or equal to 1 on the scale of Held and Pierrot Deseilligny~* Quadriceps voluntary motor skill greater than or equal to 2 on the scale of Held and Pierrot Deseilligny~* Informed consent of the patient.~Exclusion Criteria:~* - Evolutive neurological disease leading to cognitive impairment (Alzheimer's, Parkinson's, Multiple sclerosis ...)~* Pre-stroke neurological sequelae~* Achilles tendon elongation or tendinous transfer surgery.~* Spasticity of the sural triceps greater than 2 on the modified Ashworth scale~* Injection of botulinum toxin~* Patients under guardianship, curatorships or under safeguard of justice.~* Allergy to glue, skin lesions located on the zone of laying of the bands~* Complex Regional Pain Symptom of the Ankle

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAPING (Type: EXPERIMENTAL): taping in conjunction with common rehabilitation for hemiplegic patients
- NO TAPING (Type: PLACEBO_COMPARATOR): Common rehabilitation for hemiplegic patients without taping

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient affiliated to a social security regimen or beneficiary of the same~* Signed written informed consent form~* Patient, ≥ 18 years-old, with established diagnosis of myelodysplastic syndrome with low or intermediate-1 risk cytogenetic profile~* FACIT-F score ≤ 34,~* Indication of blood transfusion.~Exclusion Criteria:~* Contra-indication to experimental procedures and/or physical exercise,~* Concomitant cancer diagnosis,~* Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent~* Refusing participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MDS patients (Type: EXPERIMENTAL): MDS patients receiving blood transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-75 years~* Disease: chronic Achilles tendinopathy de novo or recurrent confirmed by ultrasound~* Patients having signed the informed consent for the study participation~* Patients covered by medical insurance~* Patients having no behavioral disorders~Exclusion Criteria:~* History of rupture of the Achilles tendon (= stage 4)~* Antibiotic treatment tendinotoxique (Quinolones, ...)~* Inability to walk more than 30 minutes per day.~* Haglund Syndrome~* Treatment of tendinopathy or being older than six months~* Minors~* Major trust

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 8° incline shoe (Type: EXPERIMENTAL): The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction).
- kinesitherapy (Type: ACTIVE_COMPARATOR): The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written consent of the patient~* Age between 18 and 80 years~* Planned for supra- or infratentorial (partial) resection of space occupying lesion (benign or malignant) or vascular neurosurgical procedure (clipping of an aneurysm, resection of an arteriovenous malformation, resection of cavernoma)~* Patients planned for MRI or CT follow-up within 72 hours after surgery~Exclusion Criteria:~* No informed consent~* Operation using only one burr hole (e.g. biopsy)~* Not able to fill out the questionnaires due to cognitive impairment or aphasia~* Not understanding German or English language~* Contraindication for MRI examination~* No postoperative MRI or CT examination planned within 72 hours after surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Early imaging: within 36 hours postoperatively. (Type: None): Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular within 36 hours after neurosurgical procedure.
- Late imaging: between 36 and 72 hours postoperatively (Type: None): Patients fulfilling eligibility criteria between 18 and 80 years old who receive MRI or CT follow-up after craniotomy for resection of a space occupying lesion (benign or malignant) or vascular between 36 and 72 hours after neurosurgical procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy